B-intervention	0	13	Cyanoacrylate
I-intervention	14	22	Adhesive
O	23	30	Reduces
B-condition	31	37	Seroma
O	38	48	Production
O	49	54	After
O	55	63	Modified
O	64	71	Radical
O	72	82	Mastectomy
O	83	85	or
O	86	100	Quadrantectomy
O	101	105	With
O	106	111	Lymph
O	112	116	Node
O	117	127	Dissection
O	127	128	-
O	128	129	A
O	130	141	Prospective
O	142	152	Randomized
O	153	161	Clinical
O	162	167	Trial
O	167	168	.

O	169	172	The
O	173	185	accumulation
O	186	188	of
O	189	194	fluid
O	194	195	,
O	196	197	a
O	198	204	seroma
O	204	205	,
O	206	208	is
O	209	210	a
O	211	219	frequent
O	220	232	complication
O	233	238	after
O	239	247	modified
O	248	255	radical
O	256	266	mastectomy
O	267	269	or
O	270	284	quadrantectomy
O	285	289	with
O	290	295	lymph
O	296	300	node
O	301	311	dissection
O	311	312	.

O	313	316	The
O	317	320	aim
O	321	323	of
O	324	327	the
O	328	335	present
O	336	341	study
O	342	345	was
O	346	348	to
O	349	356	examine
O	357	364	whether
O	365	366	a
O	367	370	new
O	371	379	adhesive
O	380	388	material
O	389	393	made
O	394	396	of
O	397	410	cyanoacrylate
O	411	414	can
O	415	426	effectively
O	427	434	provide
O	435	436	a
O	437	444	sealing
O	445	449	coat
O	450	452	to
O	453	460	tissues
O	461	464	and
O	465	469	thus
O	470	476	reduce
O	477	480	the
O	481	490	incidence
O	491	493	of
O	494	500	seroma
O	501	514	significantly
O	514	515	.

O	516	519	The
O	520	527	present
O	528	539	prospective
O	539	540	,
O	541	551	randomized
O	552	556	case
O	556	557	-
O	557	564	control
O	565	570	study
O	571	579	included
B-total-participants	580	583	128
B-eligibility	584	589	women
I-eligibility	590	594	with
I-eligibility	595	596	a
I-eligibility	597	603	breast
I-eligibility	604	610	cancer
I-eligibility	611	620	diagnosis
I-eligibility	621	624	and
I-eligibility	625	634	scheduled
I-eligibility	635	638	for
I-eligibility	639	647	modified
I-eligibility	648	655	radical
I-eligibility	656	666	mastectomy
I-eligibility	667	669	or
I-eligibility	670	684	quadrantectomy
I-eligibility	685	689	with
I-eligibility	690	695	lymph
I-eligibility	696	700	node
I-eligibility	701	711	dissection
O	712	714	in
B-location	715	727	Thessaloniki
I-location	727	728	,
I-location	729	735	Greece
O	735	736	.

O	737	739	In
B-intervention-participants	740	742	64
O	743	751	patients
O	752	753	(
O	753	758	cases
O	758	759	)
O	759	760	,
O	761	762	a
O	763	776	cyanoacrylate
O	777	785	adhesive
O	786	789	was
O	790	797	applied
O	798	800	at
O	801	804	the
O	805	814	operative
O	815	820	field
O	821	826	after
O	827	834	removal
O	835	837	of
O	838	841	the
O	842	847	tumor
O	848	851	and
O	852	857	lymph
O	858	863	nodes
O	863	864	;
O	865	868	the
O	869	878	remaining
B-control-participants	879	881	64
O	882	890	patients
O	891	897	served
O	898	900	as
O	901	904	the
B-control	905	913	controls
O	913	914	.

B-outcome	915	921	Seroma
I-outcome	922	932	production
O	933	934	(
O	934	935	P
O	936	937	=
O	938	939	.
O	939	942	001
O	942	943	)
O	943	944	,
O	945	953	drainage
O	954	962	duration
O	963	964	(
O	964	965	P
O	966	967	=
O	968	969	.
O	969	972	001
O	972	973	)
O	973	974	,
O	975	978	and
B-outcome	979	987	drainage
I-outcome	988	994	amount
O	995	996	(
O	996	997	P
O	998	999	=
O	1000	1001	.
O	1001	1004	001
O	1004	1005	)
O	1006	1010	were
O	1011	1014	all
O	1015	1028	significantly
O	1029	1033	less
O	1034	1037	for
O	1038	1043	cases
O	1044	1048	than
O	1049	1052	for
O	1053	1061	controls
O	1061	1062	.

O	1063	1066	The
O	1067	1074	results
O	1075	1079	from
O	1080	1081	a
O	1082	1090	stepwise
O	1091	1099	multiple
O	1100	1110	regression
O	1111	1116	model
O	1117	1130	incorporating
O	1131	1134	the
O	1135	1138	use
O	1139	1141	of
O	1142	1150	adhesive
O	1150	1151	,
O	1152	1156	body
O	1157	1161	mass
O	1162	1167	index
O	1167	1168	,
O	1169	1174	tumor
O	1175	1179	size
O	1179	1180	,
O	1181	1184	and
O	1185	1191	number
O	1192	1194	of
O	1195	1206	infiltrated
O	1207	1212	lymph
O	1213	1218	nodes
O	1219	1223	were
O	1224	1235	significant
O	1236	1239	and
O	1240	1244	able
O	1245	1247	to
O	1248	1255	explain
O	1256	1258	51
O	1258	1259	.
O	1259	1260	6
O	1260	1261	%
O	1262	1264	of
O	1265	1268	the
O	1269	1280	variability
O	1281	1283	in
B-outcome	1284	1290	seroma
I-outcome	1291	1297	amount
O	1297	1298	.

O	1299	1302	The
O	1303	1310	results
O	1311	1313	of
O	1314	1317	our
O	1318	1323	study
O	1324	1328	have
O	1329	1341	demonstrated
O	1342	1346	that
O	1347	1350	the
O	1351	1364	cyanoacrylate
O	1365	1373	adhesive
O	1374	1377	can
O	1378	1388	contribute
O	1389	1391	to
O	1392	1395	the
O	1396	1405	reduction
O	1406	1408	of
O	1409	1416	seromas
O	1417	1425	produced
O	1426	1431	after
O	1432	1442	mastectomy
O	1443	1446	and
O	1447	1459	subsequently
O	1460	1468	decrease
O	1469	1472	the
O	1473	1481	duration
O	1482	1484	of
O	1485	1498	postoperative
O	1499	1507	drainage
O	1508	1511	and
O	1512	1515	the
O	1516	1525	frequency
O	1526	1528	of
O	1529	1535	seroma
O	1536	1547	aspirations
O	1547	1548	.

O	1549	1556	However
O	1556	1557	,
O	1558	1565	because
O	1566	1569	the
O	1570	1582	pathogenesis
O	1583	1585	of
O	1586	1592	seroma
O	1593	1602	formation
O	1603	1605	is
O	1606	1618	multifaceted
O	1619	1622	and
O	1623	1630	complex
O	1630	1631	,
O	1632	1639	further
O	1640	1648	research
O	1649	1651	of
O	1652	1658	larger
O	1659	1665	sample
O	1666	1671	sizes
O	1672	1674	is
O	1675	1683	required
O	1684	1686	to
O	1687	1694	confirm
O	1695	1698	the
O	1699	1706	results
O	1707	1709	of
O	1710	1713	our
O	1714	1719	study
O	1719	1720	.
